CEO Adam Schechter was paid $18,339,913 in fiscal year 2025, ↓ down 5.1% from fiscal year 2024, the 69th percentile of its disclosed peer group (SEC filing 0001193125-26-150752 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$18,339,913 ↓ Adam Schechter total, FY2025 | 69th CEO pay percentile vs peers | 292:1 CEO-to-median pay ratio | 94.68% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
LH's next annual pay disclosure, estimated April 16, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Adam Schechter | $1,435,000 | $0 | $11,400,463 | $2,754,582 | $2,062,095 | $0 | $687,773 | $18,339,913 |
| President and Chief Executive Officer | ||||||||
| Julia Wang | 737,500 | 200,000 | 2,681,239 | 649,116 | 706,755 | 0 | 40,259 | 5,014,869 |
| Executive Vice President and Chief Financial Officer | ||||||||
| Mark Schroeder | 748,461 | 0 | 2,514,961 | 607,506 | 727,399 | 11,187 | 177,643 | 4,787,157 |
| Former Executive Vice President and President, Diagnostics and Chief Operations Officer | ||||||||
| Brian Caveney | 748,461 | 0 | 2,304,466 | 557,574 | 719,907 | 0 | 25,515 | 4,355,923 |
| Executive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer | ||||||||
| Megan Bailey | 568,500 | 0 | 1,257,480 | 307,914 | 547,622 | 0 | 34,751 | 2,716,267 |
| Executive Vice President and President, Central Laboratories and International | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Adam Schechter | $18,339,913 | $19,327,354 | $15,979,355 | ↓ −987,441 |
| Julia Wang | 5,014,869 | 3,362,386 | — | ↑ +1,652,483 |
| Mark Schroeder | 4,787,157 | 3,986,307 | — | ↑ +800,850 |
| Brian Caveney | 4,355,923 | 3,567,757 | — | ↑ +788,166 |
| Megan Bailey | 2,716,267 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Labcorp Holdings's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper LH reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
The list of companies that name LH as a peer is temporarily unavailable — recheck shortly.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| D. Gary Gilliland | Former director (through FY2025) | $340,000 |
| Garheng Kong | Lead Independent Director | $405,000 |
| Jeffrey A. Davis | Independent Director | $365,000 |
| John H. Sampson | Independent Director | — |
| Kathryn E. Wengel | Independent Director | $340,000 |
| Kerrii B. Anderson | Independent Director | $340,000 |
| Kirsten M. Kliphouse | Independent Director | $340,000 |
| Paul B. Rothman | Independent Director | $360,000 |
| Peter M. Neupert | Independent Director | $340,000 |
| Richelle P. Parham | Independent Director | $360,000 |
| Victor Bulto | Independent Director | $46,776 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Adam H. Schechter | Director | 2026-05-11 | D | 5,903 | $255 | $1,502,314 | Common | Form 4 ↗ |
| Kathryn W. Kyle | EVP, Chief Legal Officer | 2026-06-08 | D | 762 | 264 | 201,084 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-07-01 | — | 583 | — | — | 2 insiders, 2 accrual rows | ||
| Bryan T. Vaughn | EVP and President, Diagnostics | 2026-07-01 | D | 93 | 284 | 26,401 | Common | Form 4 ↗ |
| Bryan T. Vaughn | EVP and President, Diagnostics | 2026-07-01 | A | 327 | — | — | Common | Form 4 ↗ |
| Kathryn W. Kyle | EVP, Chief Legal Officer | 2026-07-01 | D | 73 | 284 | 20,723 | Common | Form 4 ↗ |
| Kathryn W. Kyle | EVP, Chief Legal Officer | 2026-07-01 | A | 256 | — | — | Common | Form 4 ↗ |
| Bryan T. Vaughn | EVP and President, Diagnostics | 2026-07-02 | D | 234 | 286 | 66,968 | Common | Form 4 ↗ |
| Kathryn W. Kyle | EVP, Chief Legal Officer | 2026-07-02 | D | 92 | 286 | 26,329 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-08-03 | — | 1,338 | — | — | 1 insider, 1 accrual row | ||
| Peter J. Wilkinson | SVP, Chief Accounting Officer | 2026-08-03 | A | 1,338 | 209 | 279,977 | Common | Form 4 ↗ |
| Peter J. Wilkinson | SVP, Chief Accounting Officer | 2026-08-03 | D | 82 | 309 | 25,356 | Common | Form 4 ↗ |
| Peter J. Wilkinson | SVP, Chief Accounting Officer | 2026-08-03 | D | 1,338 | 309 | 413,751 | Common | Form 4 ↗ |
| Amy B. Summy | EVP, Chief Marketing Officer | 2026-08-04 | D | 924 | 307 | 283,428 | Common | Form 4 ↗ |
| Adam H. Schechter | Director | 2026-08-11 | D | 4,669 | 320 | 1,495,808 | Common | Form 4 ↗ |
| Kerrii B. Anderson | Director | 2026-08-17 | D | 3,000 | 318 | 954,060 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-09-01 | — | 3,150 | — | — | 3 insiders, 3 accrual rows | ||
| Brian Caveney | EVP, Pres of BLS, CMO & CSO | 2026-09-01 | A | 3,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Adam H. Schechter | Director | 2026-05-11 | D | 5,903 | $255 | $1,502,314 | Common | Form 4 ↗ |
| Kathryn W. Kyle | EVP, Chief Legal Officer | 2026-06-08 | D | 762 | 264 | 201,084 | Common | Form 4 ↗ |
| Bryan T. Vaughn | EVP and President, Diagnostics | 2026-07-01 | D | 327 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bryan T. Vaughn | EVP and President, Diagnostics | 2026-07-01 | D | 93 | 284 | 26,401 | Common | Form 4 ↗ |
| Bryan T. Vaughn | EVP and President, Diagnostics | 2026-07-01 | A | 327 | — | — | Common | Form 4 ↗ |
| Kathryn W. Kyle | EVP, Chief Legal Officer | 2026-07-01 | D | 256 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kathryn W. Kyle | EVP, Chief Legal Officer | 2026-07-01 | D | 73 | 284 | 20,723 | Common | Form 4 ↗ |
| Kathryn W. Kyle | EVP, Chief Legal Officer | 2026-07-01 | A | 256 | — | — | Common | Form 4 ↗ |
| Bryan T. Vaughn | EVP and President, Diagnostics | 2026-07-02 | D | 234 | 286 | 66,968 | Common | Form 4 ↗ |
| Kathryn W. Kyle | EVP, Chief Legal Officer | 2026-07-02 | D | 92 | 286 | 26,329 | Common | Form 4 ↗ |
| Peter J. Wilkinson | SVP, Chief Accounting Officer | 2026-08-03 | D | 1,338 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter J. Wilkinson | SVP, Chief Accounting Officer | 2026-08-03 | A | 1,338 | 209 | 279,977 | Common | Form 4 ↗ |
| Peter J. Wilkinson | SVP, Chief Accounting Officer | 2026-08-03 | D | 82 | 309 | 25,356 | Common | Form 4 ↗ |
| Peter J. Wilkinson | SVP, Chief Accounting Officer | 2026-08-03 | D | 1,338 | 309 | 413,751 | Common | Form 4 ↗ |
| Amy B. Summy | EVP, Chief Marketing Officer | 2026-08-04 | D | 924 | 307 | 283,428 | Common | Form 4 ↗ |
| Adam H. Schechter | Director | 2026-08-11 | D | 4,669 | 320 | 1,495,808 | Common | Form 4 ↗ |
| Kerrii B. Anderson | Director | 2026-08-17 | D | 3,000 | 318 | 954,060 | Common | Form 4 ↗ |
| Bryan T. Vaughn | EVP and President, Diagnostics | 2026-09-01 | A | 1,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan C. Meltzer | EVP, COO | 2026-09-01 | A | 900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Akinbolade Oyegunwa | EVP, CIO & CTO | 2026-09-01 | A | 750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Caveney | EVP, Pres of BLS, CMO & CSO | 2026-09-01 | A | 3,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Adam Schechter | RSU | 2025-02-11 | — | — | 10,970 | — | $2,689,186 |
| Julia Wang | OPTION | 2025-02-11 | — | — | 7,800 | — | 649,116 |
| Brian Caveney | RSU | 2025-02-11 | — | — | 2,220 | — | 544,211 |
| Adam Schechter | PSU | 2025-02-11 | 16,455 | 32,910 | — | 65,820 | 8,711,277 |
| Adam Schechter | OPTION | 2025-02-11 | — | — | 33,100 | — | 2,754,582 |
| Mark Schroeder | PSU | 2025-02-11 | 3,630 | 7,260 | — | 14,520 | 1,921,722 |
| Brian Caveney | PSU | 2025-02-11 | 3,325 | 6,650 | — | 13,300 | 1,760,255 |
| Megan Bailey | OPTION | 2025-02-11 | — | — | 3,700 | — | 307,914 |
| Mark Schroeder | OPTION | 2025-02-11 | — | — | 7,300 | — | 607,506 |
| Julia Wang | RSU | 2025-02-11 | — | — | 2,580 | — | 632,461 |
| Brian Caveney | OPTION | 2025-02-11 | — | — | 6,700 | — | 557,574 |
| Julia Wang | PSU | 2025-02-11 | 3,870 | 7,740 | — | 15,480 | 2,048,778 |
| Megan Bailey | PSU | 2025-02-11 | 1,815 | 3,630 | — | 7,260 | 960,861 |
| Megan Bailey | RSU | 2025-02-11 | — | — | 1,210 | — | 296,619 |
| Mark Schroeder | RSU | 2025-02-11 | — | — | 2,420 | — | 593,239 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Adam Schechter | $2,689,186 | $8,711,277 | $2,754,582 | 61.5% |
| Julia Wang | 632,461 | 2,048,778 | 649,116 | 61.5% |
| Brian Caveney | 544,211 | 1,760,255 | 557,574 | 61.5% |
| Mark Schroeder | 593,239 | 1,921,722 | 607,506 | 61.5% |
| Megan Bailey | 296,619 | 960,861 | 307,914 | 61.4% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Adam Schechter | RSU | 80,260 | — | $20,135,629 |
| Julia Wang | RSU | 16,100 | — | 4,039,168 |
| Megan Bailey | RSU | 1,184 | — | 297,042 |
| Brian Caveney | RSU | 3,271 | — | 867,698 |
| Megan Bailey | RSU | 1,210 | — | 303,565 |
| Julia Wang | RSU | 1,787 | — | 448,323 |
| Megan Bailey | RSU | 7,260 | — | 1,821,389 |
| Megan Bailey | RSU | 67 | — | 16,809 |
| Megan Bailey | RSU | 360 | — | 90,317 |
| Adam Schechter | RSU | 8,920 | — | 2,237,850 |
| Adam Schechter | RSU | 10,970 | — | 2,752,154 |
| Megan Bailey | RSU | 3,220 | — | 807,834 |
| Adam Schechter | RSU | 3,249 | — | 815,109 |
| Megan Bailey | RSU | 222 | — | 55,695 |
| Adam Schechter | RSU | 65,820 | — | 16,512,922 |
| Adam Schechter | RSU | 58,470 | — | 14,668,954 |
| Julia Wang | RSU | 15,480 | — | 3,883,622 |
| Julia Wang | RSU | 2,580 | — | 647,270 |
| Megan Bailey | RSU | 740 | — | 185,651 |
Our executive compensation philosophy is to pay for performance by rewarding the achievement of specific short-term and long-term financial, operational, and strategic goals.
| CEO STI target (% of salary) | 150% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | FW Cook |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-26 | 66,519,291 | 3,735,777 | 304,147 | 94.68% | Passed |
| 2025 | 2025-05-20 | 64,147,316 | 5,634,146 | 302,186 | 91.93% | Passed |
| 2024 | 2024-05-14 | 65,007,331 | 5,566,884 | 228,974 | 92.11% | Passed |
| 2023 | 2023-05-11 | 67,568,231 | 5,578,194 | 244,678 | 92.37% | Passed |
| 2022 | 2022-05-11 | 68,952,729 | 6,439,284 | 149,934 | 91.46% | Passed |
| 2021 | 2021-05-12 | 72,236,847 | 6,915,431 | 176,279 | 91.26% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-26 | 94.68%a |
| 2025 | 2025-05-20 | 91.93%b |
| 2024 | 2024-05-14 | 92.11%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 292 : 1 |
|---|---|
| CEO total compensation | $18,355,030 |
| Median employee compensation | $62,929 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Garheng KongIndependent · Lead Independent Director · Compensation and Human Capital · Nominating and Corporate Governance (Chair) | $185,000 | $219,891 | $0 | $0 | $109 | $405,000 |
| Jeffrey A. DavisIndependent · Audit (Chair) · Quality and Compliance | 145,000 | 219,891 | 0 | 0 | 109 | 365,000 |
| Paul B. RothmanIndependent · Quality and Compliance (Chair) | 140,000 | 219,891 | 0 | 0 | 109 | 360,000 |
| Richelle P. ParhamIndependent · Compensation and Human Capital (Chair) · Nominating and Corporate Governance | 140,000 | 219,891 | 0 | 0 | 109 | 360,000 |
| Kerrii B. AndersonIndependent · Audit · Nominating and Corporate Governance | 120,000 | 219,891 | 0 | 0 | 109 | 340,000 |
| Peter M. NeupertIndependent · Nominating and Corporate Governance | 120,000 | 219,891 | 0 | 0 | 109 | 340,000 |
| Kathryn E. WengelIndependent · Quality and Compliance | 120,000 | 219,891 | 0 | 0 | 109 | 340,000 |
| Kirsten M. KliphouseIndependent · Audit | 120,000 | 219,891 | 0 | 0 | 109 | 340,000 |
| D. Gary GillilandIndependent · Not standing for re-election · Departed during FY | 120,000 | 219,891 | 0 | 0 | 109 | 340,000 |
| Victor BultoIndependent · Audit · Newly elected | 10,109 | 36,411 | 0 | 0 | 256 | 46,776 |
| John H. SampsonIndependent · Audit · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Adam H. SchechterEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $120,000 |
|---|---|
| Annual equity retainer | $219,891 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 25,000 |
| Stock ownership guideline | $600,000 |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $1,220,109 |
| Equity awards (grant-date value) | $2,015,430 |
| All other compensation | $1,237 |
| Total cost of the board | $3,236,776 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Labcorp Holdings names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Labcorp Holdings.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Tenet Healthcare Corporation | 2025 | Saum Sutaria | $1,500,000 | $31,677,365 | $0 | $9,000,000 | $43,108,969 |
| 2 | Baxter International Inc. | 2025 | Andrew Hider | 499,315 | 23,133,518 | 3,185,053 | 820,125 | 29,805,182 |
| 3 | Boston Scientific Corporation | 2025 | Michael Mahoney | 1,442,603 | 13,608,056 | 3,749,980 | 4,002,001 | 23,532,050 |
| 4 | Stryker Corporation | 2025 | Kevin Lobo | 1,500,000 | 9,764,136 | 6,920,781 | 2,250,000 | 21,401,495 |
| 5 | Labcorp Holdings | 2025 | Adam Schechter | 1,435,000 | 11,400,463 | 2,754,582 | 2,062,095 | 18,339,913 |
| 6 | Becton, Dickinson and Company Incorporated | 2025 | Thomas Polen | 1,395,463 | 9,991,854 | 3,311,861 | 1,852,010 | 17,129,140 |
| 7 | Universal Health Services | 2025 | Marc Miller | 1,430,769 | 9,999,904 | 0 | 4,292,307 | 16,148,937 |
| 8 | Zimmer Biomet Holdings, Inc. | 2025 | Ivan Tornos | 1,281,846 | 12,000,101 | 0 | 2,420,767 | 16,106,550 |
| 9 | Hologic, Inc. | 2024 | Stephen MacMillan | 1,212,628 | 9,141,468 | 2,937,477 | 1,990,413 | 15,819,261 |
| 10 | Quest Diagnostics Incorporated | 2025 | James Davis | 1,250,000 | 8,762,861 | 2,999,873 | 2,205,844 | 15,498,479 |
| 11 | Charles River Laboratories | 2025 | James Foster | 1,545,636 | 11,601,089 | 0 | 2,182,666 | 15,435,220 |
| 12 | Viatris | 2025 | Scott Smith | 1,448,654 | 10,150,013 | 0 | 2,973,660 | 15,273,331 |
| 13 | Agilent Technologies, Inc. | 2025 | Padraig McDonnell | 1,141,345 | 8,169,850 | 2,017,759 | 1,436,809 | 12,827,236 |
| 14 | Henry Schein, Inc. | 2025 | Stanley Bergman | 1,707,000 | 7,764,800 | 0 | 2,289,251 | 12,013,915 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Labcorp Holdings | 95.8% | PSU 60 · RSU 20 · Options 20 | Yes — RELATIVE TSR MODIFIER | FW Cook |
| Agilent Technologies, Inc. | not disclosed | PSU 60 · Options 20 · RSU 20 | No | Semler Brossy |
| Baxter International Inc. | not disclosed | not disclosed | No | Aon Consulting, Inc. (Aon) |
| Becton, Dickinson and Company Incorporated | 85% | PSU 50 · Options 25 · RSU 25 | No | Semler Brossy |
| Boston Scientific Corporation | 173% | PSU 50 · RSU 25 · Options 25 | No | Semler Brossy Consulting Group, LLC |
| Charles River Laboratories | 139% | PSU 60 · RSU 40 | Yes — Three-year rTSR | Pay Governance |
| Henry Schein, Inc. | 89.3% | PSU 65 · RSU 35 | No | Pearl Meyer |
| Hologic, Inc. | 109% | PSU 50 · RSU 25 · Option 25 | No | Pearl Meyer & Partners, LLC |
| Quest Diagnostics Incorporated | 113.9% | PSU 50 · RSU 25 · Options 25 | Yes — Relative TSR | Semler Brossy |
| Stryker Corporation | 100% | PSU 48 · Options 34 | No | Semler Brossy |
| Tenet Healthcare Corporation | 200% | PSU 60 · RSU 40 | No | Meridian Compensation Partners, LLC |
| Universal Health Services | 200% | RSU 50 · PSU 50 | No | FW Cook |
| Viatris | 136.72% | PSU 65 · RSU 35 | No | Meridian Compensation Partners, LLC |
| Zimmer Biomet Holdings, Inc. | 125.9% | RSU 50 · PSU 50 | Yes — Relative TSR | Semler Brossy |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Adam Schechter | DEF 14A | 2026-04-10 | 0001193125-26-150752 | Section “Summary Compensation Table” · page 65. As printed: 18,339,913. Filing ↗machine: t153 · r3 · c22 · span 3147696–3147706 |
| 2 | Section 01, Julia Wang | DEF 14A | 2026-04-10 | 0001193125-26-150752 | Section “Summary Compensation Table” · page 65. As printed: 5,014,869. Filing ↗machine: t153 · r6 · c23 · span 3177645–3177654 |
| 3 | Section 01, Mark Schroeder | DEF 14A | 2026-04-10 | 0001193125-26-150752 | Section “Summary Compensation Table” · page 65. As printed: 4,787,157. Filing ↗machine: t153 · r18 · c23 · span 3279384–3279393 |
| 4 | Section 01, Brian Caveney | DEF 14A | 2026-04-10 | 0001193125-26-150752 | Section “Summary Compensation Table” · page 65. As printed: 4,355,923. Filing ↗machine: t153 · r12 · c22 · span 3228498–3228507 |
| 5 | Section 01, Megan Bailey | DEF 14A | 2026-04-10 | 0001193125-26-150752 | Section “Summary Compensation Table” · page 65. As printed: 2,716,267. Filing ↗machine: t153 · r9 · c22 · span 3204157–3204166 |
| 6 | Section 03, Adam Schechter RSU | DEF 14A | 1900-01-01 | 0001193125-26-150752 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 3491978–3491987 |
| 7 | Section 03, Julia Wang OPTION | DEF 14A | 1900-01-01 | 0001193125-26-150752 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 3572697–3572704 |
| 8 | Section 03, Brian Caveney RSU | DEF 14A | 1900-01-01 | 0001193125-26-150752 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 3652806–3652813 |
| 9 | Section 03, Adam Schechter PSU | DEF 14A | 1900-01-01 | 0001193125-26-150752 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 3505720–3505729 |
| 10 | Section 03, Adam Schechter OPTION | DEF 14A | 1900-01-01 | 0001193125-26-150752 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 3519086–3519095 |
| 11 | Section 03, Mark Schroeder PSU | DEF 14A | 1900-01-01 | 0001193125-26-150752 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 12 | Section 03, Brian Caveney PSU | DEF 14A | 1900-01-01 | 0001193125-26-150752 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 3666544–3666553 |
| 13 | Section 03, Megan Bailey OPTION | DEF 14A | 1900-01-01 | 0001193125-26-150752 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 3626301–3626308 |
| 14 | Section 03, Mark Schroeder OPTION | DEF 14A | 1900-01-01 | 0001193125-26-150752 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 3733518–3733525 |
| 15 | Section 03, Julia Wang RSU | DEF 14A | 1900-01-01 | 0001193125-26-150752 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 3545594–3545601 |
| 16 | Section 03, Brian Caveney OPTION | DEF 14A | 1900-01-01 | 0001193125-26-150752 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 3679909–3679916 |
| 17 | Section 03, Julia Wang PSU | DEF 14A | 1900-01-01 | 0001193125-26-150752 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 3559332–3559341 |
| 18 | Section 03, Megan Bailey PSU | DEF 14A | 1900-01-01 | 0001193125-26-150752 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 3612938–3612945 |
| 19 | Section 03, Megan Bailey RSU | DEF 14A | 1900-01-01 | 0001193125-26-150752 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 3599201–3599208 |
| 20 | Section 03, Mark Schroeder RSU | DEF 14A | 1900-01-01 | 0001193125-26-150752 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 3706415–3706422 |
| 21 | Section 07, pay ratio | DEF 14A | 2026-04-10 | 0001193125-26-150752 | Section “CEO Pay Ratio”. As printed: 292 : 1. Filing ↗ |
| 22 | Section 08, Garheng Kong | DEF 14A | 2026-04-10 | 0001193125-26-150752 | Section “Director Compensation”. As printed: 405,000. Filing ↗machine: t78 · r8 · c21 · span 1535614–1535863 |
| 23 | Section 08, Jeffrey A. Davis | DEF 14A | 2026-04-10 | 0001193125-26-150752 | Section “Director Compensation”. As printed: 365,000. Filing ↗machine: t78 · r5 · c21 · span 1505764–1506013 |
| 24 | Section 08, Paul B. Rothman | DEF 14A | 2026-04-10 | 0001193125-26-150752 | Section “Director Compensation”. As printed: 360,000. Filing ↗machine: t78 · r11 · c21 · span 1565444–1565693 |
| 25 | Section 08, Richelle P. Parham | DEF 14A | 2026-04-10 | 0001193125-26-150752 | Section “Director Compensation”. As printed: 360,000. Filing ↗machine: t78 · r10 · c21 · span 1555498–1555747 |
| 26 | Section 08, Kerrii B. Anderson | DEF 14A | 2026-04-10 | 0001193125-26-150752 | Section “Director Compensation”. As printed: 340,000. Filing ↗machine: t78 · r3 · c21 · span 1485889–1486138 |
| 27 | Section 08, Peter M. Neupert | DEF 14A | 2026-04-10 | 0001193125-26-150752 | Section “Director Compensation”. As printed: 340,000. Filing ↗machine: t78 · r9 · c21 · span 1545555–1545804 |
| 28 | Section 08, Kathryn E. Wengel | DEF 14A | 2026-04-10 | 0001193125-26-150752 | Section “Director Compensation”. As printed: 340,000. Filing ↗machine: t78 · r12 · c21 · span 1575386–1575635 |
| 29 | Section 08, Kirsten M. Kliphouse | DEF 14A | 2026-04-10 | 0001193125-26-150752 | Section “Director Compensation”. As printed: 340,000. Filing ↗machine: t78 · r7 · c21 · span 1525664–1525913 |
| 30 | Section 08, D. Gary Gilliland | DEF 14A | 2026-04-10 | 0001193125-26-150752 | Section “Director Compensation”. As printed: 340,000. Filing ↗machine: t78 · r6 · c21 · span 1515719–1515968 |
| 31 | Section 08, Victor Bulto | DEF 14A | 2026-04-10 | 0001193125-26-150752 | Section “Director Compensation”. As printed: 46,776. Filing ↗machine: t78 · r4 · c21 · span 1495824–1496072 |
| 32 | Section 08, John H. Sampson | DEF 14A | 2026-04-10 | 0001193125-26-150752 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 33 | Section 08, Adam H. Schechter | DEF 14A | 2026-04-10 | 0001193125-26-150752 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 34 | Section 02, Adam H. Schechter 2026-05-11 | Form 4 | 2026-05-13 | 0000920148-26-000140 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Kathryn W. Kyle 2026-06-08 | Form 4 | 2026-06-10 | 0000920148-26-000148 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Bryan T. Vaughn 2026-07-01 | Form 4 | 2026-07-06 | 0000920148-26-000151 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Bryan T. Vaughn 2026-07-01 | Form 4 | 2026-07-06 | 0000920148-26-000151 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Bryan T. Vaughn 2026-07-01 | Form 4 | 2026-07-06 | 0000920148-26-000151 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Kathryn W. Kyle 2026-07-01 | Form 4 | 2026-07-06 | 0000920148-26-000152 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Kathryn W. Kyle 2026-07-01 | Form 4 | 2026-07-06 | 0000920148-26-000152 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Kathryn W. Kyle 2026-07-01 | Form 4 | 2026-07-06 | 0000920148-26-000152 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Bryan T. Vaughn 2026-07-02 | Form 4 | 2026-07-06 | 0000920148-26-000151 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Kathryn W. Kyle 2026-07-02 | Form 4 | 2026-07-06 | 0000920148-26-000152 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Peter J. Wilkinson 2026-08-03 | Form 4 | 2026-08-05 | 0000920148-26-000172 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Peter J. Wilkinson 2026-08-03 | Form 4 | 2026-08-05 | 0000920148-26-000172 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Peter J. Wilkinson 2026-08-03 | Form 4 | 2026-08-05 | 0000920148-26-000172 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Peter J. Wilkinson 2026-08-03 | Form 4 | 2026-08-05 | 0000920148-26-000172 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Amy B. Summy 2026-08-04 | Form 4 | 2026-08-06 | 0000920148-26-000176 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Adam H. Schechter 2026-08-11 | Form 4 | 2026-08-12 | 0000920148-26-000177 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Kerrii B. Anderson 2026-08-17 | Form 4 | 2026-08-18 | 0000920148-26-000186 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Bryan T. Vaughn 2026-09-01 | Form 4 | 2026-09-03 | 0000920148-26-000191 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Jonathan C. Meltzer 2026-09-01 | Form 4 | 2026-09-03 | 0000920148-26-000192 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Akinbolade Oyegunwa 2026-09-01 | Form 4 | 2026-09-03 | 0000920148-26-000193 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Brian Caveney 2026-09-01 | Form 4 | 2026-09-03 | 0000920148-26-000190 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 06, 2026 vote | Form 8-K | 2026-05-26 | 0000920148-26-000143 | Item 5.07 · say-on-pay result. As reported: 94.68% (votes for as printed: 66,519,291). Filing ↗ |
| 56 | Section 06, 2025 vote | Form 8-K | 2025-05-20 | 0000920148-25-000069 | Item 5.07 · say-on-pay result. As reported: 91.93% (votes for as printed: 64,147,316). Filing ↗ |
| 57 | Section 06, 2024 vote | Form 8-K | 2024-05-16 | 0000920148-24-000036 | Item 5.07 · say-on-pay result. As reported: 92.11% (votes for as printed: 65,007,331). Filing ↗ |
| 58 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 59 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 60 | Section 09b board cost (computed) | Computed | — | — | Cash 1,220,109 + equity 2,015,430 + all other 1,237 = 3,236,776, summed across the director compensation table rows.machine: formula: Σ = 3,236,776 |
| 61 | Tenet Healthcare Corporation, Section 10b CEO total | DEF 14A | 2026-04-16 | 0001193125-26-159118 | CEO total compensation as printed in Tenet Healthcare Corporation's own proxy. As printed: 43,108,969. Filing ↗machine: r4 · c34 · span 969343–969353 |
| 62 | Baxter International Inc., Section 10b CEO total | DEF 14A | 2026-03-23 | 0001628280-26-020330 | CEO total compensation as printed in Baxter International Inc.'s own proxy. As printed: 29,805,182. Filing ↗machine: r4 · c30 · span 1451066–1451076 |
| 63 | Boston Scientific Corporation, Section 10b CEO total | DEF 14A | 2026-03-18 | 0000885725-26-000025 | CEO total compensation as printed in Boston Scientific Corporation's own proxy. As printed: 23,532,050. Filing ↗machine: r2 · c27 · span 1249807–1249817 |
| 64 | Stryker Corporation, Section 10b CEO total | DEF 14A | 2026-03-23 | 0000310764-26-000013 | CEO total compensation as printed in Stryker Corporation's own proxy. As printed: 21,401,495. Filing ↗machine: t101 · r2 · c7 · span 1584979–1584989 |
| 65 | Labcorp Holdings (subject), Section 10b CEO total | DEF 14A | 2026-04-10 | 0001193125-26-150752 | CEO total compensation as printed in Labcorp Holdings's own proxy. As printed: 18,339,913. Filing ↗machine: t153 · r3 · c22 · span 3147696–3147706 |
| 66 | Becton, Dickinson and Company Incorporated, Section 10b CEO total | DEF 14A | 2025-12-18 | 0001628280-25-057846 | CEO total compensation as printed in Becton, Dickinson and Company Incorporated's own proxy. As printed: 17,129,140. Filing ↗machine: r2 · c27 · span 1173285–1173295 |
| 67 | Universal Health Services, Section 10b CEO total | DEF 14A | 2026-04-09 | 0001193125-26-148814 | CEO total compensation as printed in Universal Health Services's own proxy. As printed: 16,148,937. Filing ↗machine: span 1326856–1326866 |
| 68 | Zimmer Biomet Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-01 | 0001193125-26-135661 | CEO total compensation as printed in Zimmer Biomet Holdings, Inc.'s own proxy. As printed: 16,106,550. Filing ↗machine: t111 · r3 · c16 · span 1895785–1895795 |
| 69 | Hologic, Inc., Section 10b CEO total | DEF 14A | 2025-01-16 | 0001140361-25-001287 | CEO total compensation as printed in Hologic, Inc.'s own proxy. As printed: 15,819,261. Filing ↗machine: r2 · c25 · span 1549664–1549674 |
| 70 | Quest Diagnostics Incorporated, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001140361-26-013356 | CEO total compensation as printed in Quest Diagnostics Incorporated's own proxy. As printed: 15,498,479. Filing ↗machine: r2 · c17 · span 699327–699337 |
| 71 | Charles River Laboratories, Section 10b CEO total | DEF 14A | 2026-03-31 | 0001104659-26-037367 | CEO total compensation as printed in Charles River Laboratories's own proxy. As printed: 15,435,220. Filing ↗machine: r1 · c53 · span 1119658–1119668 |
| 72 | Viatris, Section 10b CEO total | DEF 14A | 2026-04-02 | 0001140361-26-013002 | CEO total compensation as printed in Viatris's own proxy. As printed: 15,273,331. Filing ↗machine: r2 · c28 · span 1344008–1344018 |
| 73 | Agilent Technologies, Inc., Section 10b CEO total | DEF 14A | 2026-02-06 | 0001193125-26-040286 | CEO total compensation as printed in Agilent Technologies, Inc.'s own proxy. As printed: 12,827,236. Filing ↗machine: r3 · c29 · span 1450982–1450992 |
| 74 | Henry Schein, Inc., Section 10b CEO total | DEF 14A | 2026-04-08 | 0001193125-26-146317 | CEO total compensation as printed in Henry Schein, Inc.'s own proxy. As printed: 12,013,915. Filing ↗machine: t221 · r3 · c35 · span 671366–671376 |
| 75 | Section 10a, Boston Scientific Corporation reciprocity | DEF 14A | — | 0000885725-26-000025 | Boston Scientific Corporation's most recent proxy was read; its disclosed peer group does not include Labcorp Holdings. Filing ↗ |
| 76 | Section 10a, Viatris reciprocity | DEF 14A | — | 0001140361-26-013002 | Viatris's most recent proxy was read; its disclosed peer group does not include Labcorp Holdings. Filing ↗ |
| 77 | Section 10a, Zimmer Biomet Holdings, Inc. reciprocity | DEF 14A | — | 0001193125-26-135661 | Zimmer Biomet Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include Labcorp Holdings. Filing ↗ |
| 78 | Section 10a, Tenet Healthcare Corporation reciprocity | DEF 14A | — | 0001193125-26-159118 | Tenet Healthcare Corporation's most recent proxy was read; its disclosed peer group does not include Labcorp Holdings. Filing ↗ |
| 79 | Section 10a, Henry Schein, Inc. reciprocity | DEF 14A | — | 0001193125-26-146317 | Henry Schein, Inc.'s most recent proxy was read; its disclosed peer group does not include Labcorp Holdings. Filing ↗ |
| 80 | Section 10a, Quest Diagnostics Incorporated reciprocity | DEF 14A | — | 0001140361-26-013356 | Quest Diagnostics Incorporated names Labcorp Holdings in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 81 | Section 10a, Universal Health Services reciprocity | DEF 14A | — | 0001193125-26-148814 | Universal Health Services's most recent proxy was read; its disclosed peer group does not include Labcorp Holdings. Filing ↗ |
| 82 | Section 10a, Charles River Laboratories reciprocity | DEF 14A | — | 0001104659-26-037367 | Charles River Laboratories's most recent proxy was read; its disclosed peer group does not include Labcorp Holdings. Filing ↗ |
| 83 | Section 10a, Baxter International Inc. reciprocity | DEF 14A | — | 0001628280-26-020330 | Baxter International Inc. names Labcorp Holdings in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 84 | Section 10a, Stryker Corporation reciprocity | DEF 14A | — | 0000310764-26-000013 | Stryker Corporation names Labcorp Holdings in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 85 | Section 10a, Agilent Technologies, Inc. reciprocity | DEF 14A | — | 0001193125-26-040286 | Agilent Technologies, Inc. names Labcorp Holdings in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 86 | Section 10a, Becton, Dickinson and Company Incorporated reciprocity | DEF 14A | — | 0001628280-25-057846 | Becton, Dickinson and Company Incorporated's most recent proxy was read; its disclosed peer group does not include Labcorp Holdings. Filing ↗ |
| 87 | Section 10a, Hologic, Inc. reciprocity | DEF 14A | — | 0001140361-25-001287 | Hologic, Inc.'s most recent proxy was read; its disclosed peer group does not include Labcorp Holdings. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.